Apogee Therapeutics (APGE) Other financing activities (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Other financing activities data on file, last reported at $17.2 million in Q1 2026.

• Quarterly Other financing activities rose 54.19% year-over-year to $17.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.3 million (up 72.79% YoY) and the FY2025 annual result came in at $46.3 million, up 98.34% from the prior year.
• Other financing activities improved to $17.2 million in Q1 2026 per APGE's latest filing, from $11.9 million in the prior quarter.
• Across five years, Other financing activities topped out at $177.5 million in Q3 2023 and bottomed at -$173.8 million in Q4 2023.
• The 4-year median for Other financing activities is $7.6 million (2024), against an average of $7.1 million.
• Peak annual rise in Other financing activities reached 411.95% in 2024, while the deepest fall reached 96.71% in 2024.
• Tracing APGE's Other financing activities over 4 years: stood at -$173.8 million in 2023, then surged by 104.38% to $7.6 million in 2024, then jumped by 56.79% to $11.9 million in 2025, then jumped by 43.8% to $17.2 million in 2026.
• Per Business Quant, the three latest APGE Other financing activities figures stand at $17.2 million (Q1 2026), $11.9 million (Q4 2025), and $11.9 million (Q3 2025).

Peer Comparison